<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&nbsp;
July 17, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Brainstorm Cell Therapeutics Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified
in its charter) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 34%; vertical-align: top; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 31%; vertical-align: top; font-weight: bold; text-align: center">000-54365</TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 31%; vertical-align: top; font-weight: bold; text-align: center">20-8133057</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-style: italic; text-align: center">(State or other jurisdiction of<BR> incorporation)</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-style: italic; text-align: center">(Commission File No.)</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-style: italic; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; text-align: center"><B>605 Third Avenue, 34<SUP>th</SUP> Floor </B></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">New York, NY</TD>
    <TD STYLE="font-weight: bold; text-align: center">10158</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-style: italic; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(646) 666-3188 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Registrant&rsquo;s telephone number,
including area code) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Former name or former address, if changed
since last report) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o </FONT>Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o </FONT>Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o </FONT>Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o </FONT>Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold">Item 1.01&nbsp;</TD>
    <TD STYLE="width: 88%; font-weight: bold">Entry into a Material Definitive Agreement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: black; background-color: white">On
July 17, 2012, </FONT>Brainstorm Cell Therapeutics Inc.<FONT STYLE="color: black; background-color: white">, a Delaware corporation
(the &ldquo;Company&rdquo;), entered into a securities purchase agreement (the &ldquo;Securities Purchase Agreement&rdquo;) with
several investors (the &ldquo;Investors&rdquo;) relating to the sale and issuance by the Company to the Investors of an aggregate
of 19,818,972 shares of its common stock, par value $0.00005 per share (&ldquo;Common Stock&rdquo;), at a price per share of $0.29.
Investors also received a 30 month warrant to purchase 0.75 shares of Common Stock for every share purchased in the offering (the
&ldquo;Offering&rdquo;), at an exercise price of $0.29 per share (each, a &ldquo;Warrant,&rdquo; and collectively, the &ldquo;Warrants&rdquo;).&nbsp;
</FONT>The net proceeds to the Company from the Offering, after deducting the placement agent&rsquo;s fees and Offering expenses
are approximately $<FONT STYLE="background-color: white">4.9</FONT>&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">The
Company registered the Offered Shares and Warrants pursuant to a registration statement on Form S-1 (File No. 333-179331) (the
&ldquo;Registration Statement&rdquo;), which was declared effective by the Securities and Exchange Commission on July 13, 2012.&nbsp;&nbsp;The
closing of the Offering occurred on July 19, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
connection with the Offering, the Company also entered into a Placement Agency Agreement with Maxim Group LLC (the &ldquo;Placement
Agent&rdquo;), dated as of July 17, 2012, pursuant to which the Company paid the Placement Agent a cash fee equal to 6% of the
gross proceeds of the Offering and a corporate finance fee of 1% of the gross proceeds of the Offering, as well as fees and expenses
of the Placement Agent of $100,000.&nbsp;&nbsp;In addition, the Company issued to the Placement Agent a 2-year warrant to purchase
up to 594,569 shares of Common Stock (equal to 3% of the number of shares sold in the Offering), with an exercise price equal to
$0.348 (120% of the public offering price). Leader Underwriters (1993) Ltd. acted as a sub-agent of the Placement Agent for the
sole purpose of arranging for the sale of securities registered under this registration statement to investors in Israel, and received
payment directly from the Placement Agent out of the consideration paid by Company to Placement Agent. The offering of securities
in Israel was pursuant to an exemption from the registration requirements in Israel and was considered a private placement in Israel
under Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Securities
Purchase Agreement contains provisions that restrict the Company from issuing, except in certain cases, any Common Stock or Common
Stock equivalents in the first 90 days following the closing of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">The
Warrants are exercisable until the 30 month anniversary of the date of issuance.&nbsp;&nbsp;The Warrants will be exercisable, at
the option of each holder, in whole or in part by delivering to the Company a duly executed exercise notice accompanied by payment
of the exercise price</FONT>. Warrant holders also receive consideration in the event of certain pro rata issuances or sales or
distributions to the holders of Common Stock<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">On
July 17, 2012, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached
as Exhibit 99.1 hereto. On July 19, 2012, the Company issued a press release announcing the closing of the Offering. A copy of
the press release is attached as Exhibit 99.2 hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The form of Warrant,
the form of the Securities Purchase Agreement, the form of Placement Agency Agreement and the form of Placement Agent Warrant are
filed as Exhibits 4.1, 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K.&nbsp;&nbsp;<FONT STYLE="background-color: white">The
foregoing descriptions of the Securities Purchase Agreement, the Warrants, the Placement Agency Agreement and the Placement Agent
Warrant do not purport to be complete and are qualified in their entirety by reference to the Exhibits 4.1, 10.1, 10.2 and 10.3
hereto which are incorporated herein by reference. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold">Item 9.01&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 88%">Financial Statements and Exhibits</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exhibits listed in the Exhibit&nbsp;Index below are filed
with this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>July 20, 2012</TD>
    <TD COLSPAN="2">Brainstorm Cell Therapeutics Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Liat Sossover</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Liat Sossover</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: windowtext 1pt solid">Exhibit<BR> No.</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: windowtext 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>4.1</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Form of Warrant, incorporated herein by reference to Annex B of the Company&rsquo;s Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>10.1</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Form of Securities Purchase Agreement, incorporated herein by reference to Annex A of the Company&rsquo;s Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>10.2</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Form of Placement Agency Agreement by and between Brainstorm Cell Therapeutics Inc. and Maxim Group LLC, incorporated herein by reference to Exhibit 10.58 of the Company&rsquo;s Registration Statement filed June 29, 2012 (File No. 333-179331)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>10.3</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Form of Common Stock Purchase Warrant issued by Brainstorm Cell Therapeutics Inc. to Placement Agent, incorporated herein by reference to Exhibit A of Exhibit 10.58 of the Company&rsquo;s Registration Statement filed June 29, 2012 (File No. 333-179331)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>99.1</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Press Release dated July 17, 2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>99.2</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Press Release dated July 19, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v319070_8k.htm", "description": "8-K", "secsgml_size_bytes": 20255}]
{"company-data": {"conformed-name": "BRAINSTORM CELL THERAPEUTICS INC", "cik": "0001137883", "assigned-sic": "2836", "irs-number": "912061050", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54365", "film-number": "12971487"}, "business-address": {"street1": "110 EAST 59TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10019", "phone": "250-519-0553"}, "mail-address": {"street1": "110 EAST 59TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10019"}, "former-company": [{"former-conformed-name": "GOLDEN HAND RESOURCES INC", "date-changed": "20030827"}, {"former-conformed-name": "WIZBANG TECHNOLOGIES INC", "date-changed": "20010409"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 
July 17, 2012
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
000-54365
20-8133057
(State or other jurisdiction of
incorporation)
(Commission File No.)
(IRS Employer Identification No.)
605 Third Avenue, 34
th
Floor
New York, NY
10158
(Address of principal executive offices)
(Zip Code)
(646) 666-3188
(Registrant's telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement.
On
July 17, 2012,
Brainstorm Cell Therapeutics Inc.
, a Delaware corporation
(the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with
several investors (the "Investors") relating to the sale and issuance by the Company to the Investors of an aggregate
of 19,818,972 shares of its common stock, par value $0.00005 per share ("Common Stock"), at a price per share of $0.29.
Investors also received a 30 month warrant to purchase 0.75 shares of Common Stock for every share purchased in the offering (the
"Offering"), at an exercise price of $0.29 per share (each, a "Warrant," and collectively, the "Warrants").
The net proceeds to the Company from the Offering, after deducting the placement agent's fees and Offering expenses
are approximately $
4.9
million.
The
Company registered the Offered Shares and Warrants pursuant to a registration statement on Form S-1 (File No. 333-179331) (the
"Registration Statement"), which was declared effective by the Securities and Exchange Commission on July 13, 2012.  The
closing of the Offering occurred on July 19, 2012.
In
connection with the Offering, the Company also entered into a Placement Agency Agreement with Maxim Group LLC (the "Placement
Agent"), dated as of July 17, 2012, pursuant to which the Company paid the Placement Agent a cash fee equal to 6% of the
gross proceeds of the Offering and a corporate finance fee of 1% of the gross proceeds of the Offering, as well as fees and expenses
of the Placement Agent of $100,000.  In addition, the Company issued to the Placement Agent a 2-year warrant to purchase
up to 594,569 shares of Common Stock (equal to 3% of the number of shares sold in the Offering), with an exercise price equal to
$0.348 (120% of the public offering price). Leader Underwriters (1993) Ltd. acted as a sub-agent of the Placement Agent for the
sole purpose of arranging for the sale of securities registered under this registration statement to investors in Israel, and received
payment directly from the Placement Agent out of the consideration paid by Company to Placement Agent. The offering of securities
in Israel was pursuant to an exemption from the registration requirements in Israel and was considered a private placement in Israel
under Israeli law.
The Securities
Purchase Agreement contains provisions that restrict the Company from issuing, except in certain cases, any Common Stock or Common
Stock equivalents in the first 90 days following the closing of the Offering.
The
Warrants are exercisable until the 30 month anniversary of the date of issuance.  The Warrants will be exercisable, at
the option of each holder, in whole or in part by delivering to the Company a duly executed exercise notice accompanied by payment
of the exercise price
. Warrant holders also receive consideration in the event of certain pro rata issuances or sales or
distributions to the holders of Common Stock
.
On
July 17, 2012, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached
as Exhibit 99.1 hereto. On July 19, 2012, the Company issued a press release announcing the closing of the Offering. A copy of
the press release is attached as Exhibit 99.2 hereto.
The form of Warrant,
the form of the Securities Purchase Agreement, the form of Placement Agency Agreement and the form of Placement Agent Warrant are
filed as Exhibits 4.1, 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K.
The
foregoing descriptions of the Securities Purchase Agreement, the Warrants, the Placement Agency Agreement and the Placement Agent
Warrant do not purport to be complete and are qualified in their entirety by reference to the Exhibits 4.1, 10.1, 10.2 and 10.3
hereto which are incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits
The exhibits listed in the Exhibit Index below are filed
with this report.
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
July 20, 2012
Brainstorm Cell Therapeutics Inc.
By:
/s/ Liat Sossover
Liat Sossover
Chief Financial Officer
EXHIBIT INDEX
Exhibit
No.
Description
4.1
Form of Warrant, incorporated herein by reference to Annex B of the Company's Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331)
10.1
Form of Securities Purchase Agreement, incorporated herein by reference to Annex A of the Company's Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331)
10.2
Form of Placement Agency Agreement by and between Brainstorm Cell Therapeutics Inc. and Maxim Group LLC, incorporated herein by reference to Exhibit 10.58 of the Company's Registration Statement filed June 29, 2012 (File No. 333-179331)
10.3
Form of Common Stock Purchase Warrant issued by Brainstorm Cell Therapeutics Inc. to Placement Agent, incorporated herein by reference to Exhibit A of Exhibit 10.58 of the Company's Registration Statement filed June 29, 2012 (File No. 333-179331)
99.1
Press Release dated July 17, 2012
99.2
Press Release dated July 19, 2012